Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β
Elizabeth C. Mormino(Allen Institute for Brain Science), Reisa A. Sperling(Harvard University), Michael Donohue(Alzheimer’s Disease Neuroimaging Initiative), Paul Aisen(University of California, San Diego), Jonathan Jackson(Harvard University), Bernard Hanseeuw(Cliniques Universitaires Saint-Luc), Jennifer R. Gatchel(Harvard University), Yakeel T. Quiroz(Harvard University), Gad A. Marshall, Nancy J. Donovan(Brigham and Women's Hospital), Kathryn V. Papp(Brigham and Women's Hospital), Dorene M. Rentz(Brigham and Women's Hospital), Rebecca E. Amariglio(Harvard University), Jasmeer P. Chhatwal(Harvard University), Keith A. Johnson(Brigham and Women's Hospital), Aaron P. Schultz(Harvard University)
Cited by 202
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k